References
- 1. S. Miura, S. S. Karnik and K. Saku, Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects, J. Renin-Angiotensin-Aldosterone Sys. 12 (2011) 1-7; DOI: 10.1177/ 1470320310370852.
- 2. M. Burnier and H. R. Brunner, Angiotensin II receptor antagonists, Lancet 355 (2000) 637-645; DOI: 10.1016/S0140-6736(99)10365-9.
- 3. A. Lant, Diuretic drugs progress in clinical pharmacology, Drugs 31 (1986) 40-55; DOI: 10.2165/ 00003495-198600314-00006.
- 4. J. M. Neutel, E. Saunders, G. L. Bakris, W. C. Cushman, K. C. Ferdinand, E. O. Ofili, J. R. Sowers and M. A. Weber, The efficacy and safety of low- and high dose fixed combinations of irbesartan/ hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The inclusive trial, J. Clin. Hyperten. 7 (2005) 578-586; DOI: 10.1111/j.1524-6175.2004.04720.x.
- 5. M. R. Weir, J. M. Neutel, A. Bhaumik, M. E. D. Obaldia and P. Lapuerta, The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk, J. Clin. Hyperten. 9 (2007) 23-30; DOI: 10.1111/ j.1524-6175.2007.07805.x.
- 6. H. E. Abdellatef, Extractive-spectrophotometric determination of disopyramide and irbesartan in their pharmaceutical formulation, Spectrochim. Acta A 66 (2007) 1248-1254; DOI: 10.1016/j. saa.2006.06.015.
- 7. S. R. El-Shaboury, S. A. Hussein, N. A. Mohamed and M. M. El-Sutohy, Spectrofluorimetric method for determination of some angiotensin II receptor antagonists, J. Pharm. Biomed. Anal. 2 (2012) 12-18; DOI: 10.1016/j.jpha.2011.10.005.
- 8. B. Bozal, B. Doghan-Topal, B. Uslu, S. A. Özkan and H. Y. Aboul-Enein, Quantitative analysis of irbesartan in pharmaceuticals and human biological fluids by voltammetry, Anal. Lett. 42 (2009) 2322-2338; DOI: 10.1080/00032710903137491.
- 9. I. H. I. Habib, S. A. Weshahy, S. Toubar and M. M. A. El-Alamin, Adsorptive stripping voltammetric determination of irbesartan in bulk and pharmaceutical products, Pharm. Chem. J. 42 (2008) 438-442; DOI: 10.1007/s11094-008-0144-4.
- 10. S.-Y. Chang, D. B. Whigan, N. N. Vachharajani and R. Patel, High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine, J. Chromatogr. B 702 (1997) 149-155; DOI: 10.1016/S0378-4347(97)00387-3.
- 11. E. Martín, O. Hernández, F. Jiménez and J. J. Arias, Simultaneous spectrophotometric determination of hydrochlorothiazide and pharmaceutical preparations, Anal. Lett. 28 (1995) 1449-1464; DOI: 10.1080/00032719508006406.
- 12. M. Omar, Spectrophotometric and spectrofluorimetric determination of certain diuretics through ternary complex formation with eosin and lead (II), J. Fluoresc. 20 (2010) 275-281; DOI: 10.1007/ s10895-009-0551-2.
- 13. B. Rezaei and S. Damiri, Multiwalled carbon nanotubes modified electrode as a sensor for adsorptive stripping voltammetric determination of hydrochlorothiazide, Sensors J. IEEE 8 (2008) 1523-1529; DOI: 10.1109/jsen.2008.923585.
- 14. G. Carlucci, G. Palumbo, P. Mazzeo and M. Giovanna Quaglia, Simultaneous determination of losartan and hydrochlorothiazide in tablets by high-performance liquid chromatography, J. Pharm. Biomed. Anal. 23 (2000) 185-189; DOI: 10.1016/S0731-7085(00)00268-5.
- 15. M. Kartal and N. Erk, Simultaneous determination of hydrochlorothiazide and amiloride hydrochloride by ratio spectra derivative spectrophotometry and high-performance liquid chromatography, J. Pharm. Biomed. Anal. 19 (1999) 477-485; DOI: 10.1016/S0731-7085(98)00241-6.
- 16. S. Hillaert, K. De Grauwe and W. Van den Bossche, Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis, J. Chromatogr. A 924 (2001) 439-449; DOI: 10.1016/S0021-9673(01)00714-2.
- 17. J. Joseph-Charles, S. Brault, C. Boyer, M. H. Langlois, L. Cabrero and J. P. Dubost, Simultaneous determination of irbesartan and hydrochlorothiazide in tablets by derivative spectrophotometry, Anal. Lett. 36 (2003) 2485-2495; DOI: 10.1081/al-120024337.
- 18. C. Vetuschi, A. Giannandrea, G. Carlucci and P. Mazzeo, Determination of hydrochlorothiazide and irbesartan in pharmaceuticals by fourth-order UV derivative spectrophotometry, Farmaco 60 (2005) 665-670; DOI: 10.1016/j.farmac.2005.04.013.
- 19. A. S. Khodke, L. V. Potale, M. C. Damle and K. G. Bothara, A validated stability indicating HPTLC method for simultaneous estimation of irbesartan and hydrochlorothiazide, Pharm. Methods 1 (2010) 39-43; DOI: 10.4103/2229-4708.72229.
- 20. F. Coudoré, L. Harvard, S. Lefeuvre, E. M. Billaud, P. Beaune, G. Bobrie, M. Azizi, P. Prognon and S. Laurent, HPLC-DAD Analysis of hydrochlorothiazide and irbesartan in hypertensive patients on fixed-dose combination therapy, Chromatographia 74 (2011) 559-565; DOI: 10.1007/ s10337-011-2111-6.
- 21. N. Sultana, M. S. Arayne, S. S. Ali and S. Sajid, Simultaneous determination of olmesartan medoxomil and irbesartan and hydrochlorothiazide in pharmaceutical formulations and human serum using high performance liquid chromatography, Chin. J. Chromatogr. 26 (2008) 544-549; DOI: 10.1016/S1872-2059(08)60029-2.
- 22. N. Erk, Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by liquid chromatography, J. Chromatogr. B 784 (2003) 195-201; DOI: 10.1016/S1570-0232(02) 00759-6.
- 23. L. F. Tutunji, M. F. Tutunji, M. I. Alzoubi, M. H. Khabbas and A. I. Arida, Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies, J. Pharm. Biomed. Anal. 51 (2010) 985-990; DOI: 10.1016/j.jpba.2009.10.023.
- 24. Z. Vuji}, N. Mulavdi}, M. Smaji}, J. Brbori} and P. Stankovi}, Simultaneous analysis of irbesartan and hydrochlorothiazide: An improved HPLC method with the aid of a chemometric protocol, Molecules 17 (2012) 3461-3474; DOI: 10.3390/molecules17033461.
- 25. F. Gerber, M. Krummen, H. Potgeter, A. Roth, C. Siffrin and C. Spoendlin, Practical aspects of fast reversed-phase high-performance liquid chromatography using 3 μm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice, J. Chromatogr. A 1036 (2004) 127-133; DOI: 10.1016/j.chroma. 2004.02.056.
- 26. R. Plumb, G. Dear, D. Mallett and J. Ayrton, Direct analysis of pharmaceutical compounds in human plasma with chromatographic resolution using an alkyl-bonded silica rod column, Rapid Commun. Mass Spectrom. 15 (2001) 986-993; DOI: 10.1002/rcm.329.
- 27. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneve November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/ Step4/Q2_R1__Guideline.pdf; January 9, 2014.
- 28. Department of Health and Human Services, Food and Drug Administration, Maryland, USA, Analytical Procedures and Methods Validation, Chemistry, Manufacturing, and Controls Documentation., US FDA, Silver Spring (MD), August 2000; http://www.fda.gov/downloads/Drugs/ Guidances/ucm122858.pdf; January 9, 2014.
- 29. V. P. Rane, K. R. Patil, J. N. Sangshetti, R. D. Yeole and D. B. Shinde, Stability indicating LC method for simultaneous determination of irbesartan and hydrochlorothiazide in pharmaceutical preparations, J. Chromatogr Sci. 48 (2010) 595-600; DOI: 10.1093/chromsci/48.7.595.